The serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug's cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug's life, from discovery and development through postmarketing research. The integrated approach to cardiac safety presented by Turner and Durham should be of interest and value to all concerned with the drug discovery, development, marketing, and surveillance phases of the pharmaceutical endeavor. During the past two to three decades, the pharmaceutical industry has adopted a progressively more integrated approach to the drug discovery process